Currently, therapeutic strategies targeting MSLN have gradually expanded from traditional monoclonal antibody drugs to fields such as oncolytic viruses, cancer vaccines, and CAR-T cell therapy, with some clinical trials demonstrating certain antitumor efficacy. The gene discussed is MSLN; the disease is cancer.